Most California Cities Still Ban Cannabis Retail, and the State’s Own Seizure Data Show Where That Leads
California cannabis local bans leave 302 of the state's 540 cities and counties without a single licensed retailer, according to the Department of Cannabis Control's own figures. State seizure data covering October 2022 through August 2025 found 96.6…
Three Months After Hemani, Congress Has Not Moved. The Justice Department Has.
The Hemani marijuana gun ban ruling came down on June 18, 2026, and the judgment was unanimous even though the opinion was not. The Court rejected the government's categorical theory while expressly reserving cases involving addiction, present…
Louisiana Allows 5 mg THC Seltzers. Federal Law Is About to Allow 0.4 mg. Here Is What That Collision Means
The Louisiana THC drinks law permits five milligrams of total THC per twelve ounce serving, sold under an Office of Alcohol and Tobacco Control permit to adults twenty-one and over. The amended federal hemp definition caps finished products at 0.4…
German Cannabis Legalization Rollback: June 30, 2026 Update
German state interior ministers are moving to roll back federal cannabis legalization despite supporting evidence, potentially disrupting implementation and patient access. This policy shift reflects broader tensions between regulatory frameworks and…
Policy Watch: 20 Regulatory Updates — June 22, 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has issued the cumyl-pegaclone schedule i designation, reflecting its high abuse potential and lack of accepted medical use. This designation highlights regulatory efforts to control synthetic cannabinoids. Clinicians should be aware of the risks…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has issued temporary scheduling orders placing 2-fluorodeschloroketamine into Schedule I. These orders address emerging synthetic drugs and their regulatory challenges. Temporary scheduling orders are critical for managing novel substances with…
Policy Watch: 20 Regulatory Updates — June 21, 2026
This Policy Watch covers schedules of controlled substances placement June 2026 updates with 20 key regulatory items. The DEA's recent actions focus on synthetic cannabinoids and other substances. These changes affect clinical relevance and regulatory…
International Cannabis Policies and Their Association with Cannabis Use, Cannabis Use Disorder, and Other Psychiatric Disorders
International cannabis policies shape cannabis use and cannabis use disorder prevalence worldwide. Commercialized legalization is linked to increased cannabis use disorder rates. However, associations with broader psychiatric disorders remain…